TrialTargeted oncology2025

Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer.

Melissa L Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.